ReviewJournal of bioenergetics and biomembranes1993
Spectrum of mutations in cystic fibrosis.
Review in Journal of bioenergetics and biomembranes, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 18 citations in OpenAlex.
- The Ion channel, CFTR, assembles with HIPPO pathway proteins TAZ and YAP in polycystic kidney disease.The Journal of biological chemistry · 2026Article
- Development of rAAV2-CFTR: History of the First rAAV Vector Product to be Used in Humans.Human gene therapy methods · 2016Review
- Correcting the cystic fibrosis disease mutant, A455E CFTR.PloS one · 2014Article
- Cystic fibrosis transmembrane conductance regulator (ABCC7) structure.Cold Spring Harbor perspectives in medicine · 2013Review
- Ubiquitination and degradation of CFTR by the E3 ubiquitin ligase MARCH2 through its association with adaptor proteins CAL and STX6.PloS one · 2013Article
- Introduction to section IV: biophysical methods to approach CFTR structure.Methods in molecular biology (Clifton, N.J.) · 2011Article
- Frontiers in research on cystic fibrosis: understanding its molecular and chemical basis and relationship to the pathogenesis of the disease.Journal of bioenergetics and biomembranes · 1997Review
- Functional expression and apical localization of the cystic fibrosis transmembrane conductance regulator in MDCK I cells.The Biochemical journal · 1997Article
- Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations.Nature medicine · 1996Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cystic fibrosis (CF) is a disorder characterized by elevated sweat electrolytes and thick mucous secretions due to abnormal chloride permeability in epithelial tissues. The gene responsible for this disease, the CF transmembrane conductance regulator (CFTR) was identified by a positional cloning approach 3 years ago. Since that time, over two hundred mutations have been found in CFTR genes from affected individuals. Analysis of these disease-associated mutations has provided new insight into the etiology of this disease and into the mechanisms of epithelial electrolyte secretion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.